. The meeting, which consisted largely of invited lectures, presented a state-of-the-art overview of the genetic and molecular mechanisms that link obesity and hypertension. The over 40 oral presentations were supplemented by around 90 poster presentations from 34 countries. The meeting was attended by around 250 participants from 54 countries. This paper briefly reviews the contents of the invited lectures presented at this meeting covering topics ranging from genetics, molecular mechanisms, pathophysiology, cardiovascular risk, to the management of patients with obesity-related hypertension. Stimulated by the continuing success of these Symposia, the organizers are currently planning to hold a Fourth International Symposium on Obesity and Hypertension (ISOH'05) in Berlin: a tentative date for this meeting has been set for
Introduction
The Third International Symposium on Obesity and Hypertension (ISOH '03) was held on 23-25 October, 2003 , at the Max Delbrück Center for Molecular Medicine in Berlin, Germany. The meeting, which consisted largely of invited lectures, presented a state of the art overview of the genetic and molecular mechanisms that link obesity and hypertension. In addition, a number of talks focusing on the global impact of the obesity epidemic as well as presentations dealing with the metabolic complications of obesity were presented. The over 40 oral presentations were supplemented by around 90 poster presentations from 34 countries, 1 including North America, Eastern and Western Europe, the Middle East, South Asia, China, Australia, and Africa. The meeting was attended by around 250 participants from 54 countries. This report includes a summary of selected presentations on epidemiological, genetic, physiological, cellular, and pharmacological aspects of the relationship between obesity and hypertension presented at this meeting. Intervention possibilities are also discussed.
Population studies on obesity and hypertension
The global implications of the obesity epidemic and its relationship to cardiovascular risk was put into perspective in the opening lecture given by Salim Yusuf (McMaster University, Hamilton, Ontario, Canada). 2, 3 He discussed the tremendous impact of industrialization and urbanization on the worldwide prevalence of obesity and presented data from several large ongoing studies including the Prospective Urban Rural Epidemiologic Study (PURE). This pilot study involving over 8000 individuals recruited from rural populations and urban populations in Southern India clearly demonstrates marked differences in BMI and abdominal obesity as well as the prevalence of hypertension and other cardiovascular risk factors in the urban population. Salim Yusuf also presented data from the INTERHEART study, an international case-control study involving over 28 000 individuals from 52 countries demonstrating that measures of abdominal obesity (waist circumference or waist-to-hip ratio) predicted clinical events in all ethnic groups, with little added predictive value from measuring BMI. Tessa van der Merwe (Department of Medicine, Johannesburg
Hospital, South Africa) discussed the importance of obesity, which now reaches 55% in Black South Africans, in the development of insulinopenic type 2 diabetes in South Africa. She attributed this preponderance of diabetic risk both to low birth weight and to the thrifty genotype hypothesis. She highlighted the complexity of prevention and management of obesity in South Africa due to different traditional and cultural perceptions of body size. 4, 5 Epidemiological data on obesity and hypertension in Latin American and the Caribbean were presented from Margaret E Diaz (Centre for Academic Medical Research, Montevideo, Uruguay). 6 The prevalence of hypertension ranges from 11% in some regions of Bolivia to 32% in certain geographic regions of Brazil and Mexico. Similarly, the prevalence of obesity ranges from 14% in Colombia to over 30% in Paraguay. Not surprisingly, the percentage of obese individuals who also present with hypertension is high, reaching 44% in Argentina, 47% in Brazil, and 46% in Mexico. Conversely, the percentage of hypertensives who also present with obesity is 44% in Brazil, 42% in Jamaica, 45% in Uruguay, and 74% in Venezuela. The European perspective was presented by the organizer of ISOH'03, Arya M Sharma (McMaster University, Hamilton, Ontario, Canada). He presented data on behalf of the HYDRA Study group on the point prevalence of obesity and hypertension in over 45 000 unselected consecutive primary care attendees, recruited from a representative nationwide sample of primary care physicians in Germany. 7, 8 In this study, over 38% of patients were found to have a BMI greater than 25 kg/m 2 , whereas 19% of all patients had a BMI greater than 30 kg/m 2 . Overall physician's recognition of overweight (20-30%) and obesity (50-65%) was low and intervention rates were even lower (18% in the last 12 months).
Genetics
The 'Genetics' Sessions were opened by Claude Bouchard (Pennington Medical Research Center, Baton Rouge, USA). 9, 10 He presented the results of a number of genetic analyses that looked at candidate genes and the genome wide distributions of genes linked to either hypertension and obesity or both conditions. He highlighted the fact that a number of polymorphisms that have been associated with hypertension have also been associated with increased risk for obesity. Similarly, Anthony G Comuzzie (South West Foundation for Biomedical Research, San Antonio, TX, USA) pointed out that there is now a consistent pattern of replications beginning to emerge across ethnic populations with regard to certain quantatitive trait loci that appear to influence both obesity and obesity-related phenotypes. Some of these signals localize near genes that have been previously considered as a priori candidate genes, several others offer evidence for as yet unsuspected genes.
11,12
Turning from genome-wide genetic data to proven obesity and diabetes genes, Philipe Froguel (Institute of Biology F CNRS, Pasteur Institute, Lile, France and Hammersmith Genome Centre, Imperial College, London, UK) summarized the current knowledge regarding rare monogenic forms of obesity including mutations in leptin, leptin receptor, and pro-opiomelanocortin (POMC), which are responsible for massive early onset obesity associated with various endocrine abnormalities. 13 On chromosome 10p, the Gad2 gene encodes glutamate decarboxylase. SNPs in the promoter of Gad2 are associated with morbid obesity. These genetic data are strongly supported by in vitro and in vivo human functional studies, suggesting that the increased activity of Gad2 modulates food intake behaviour through increasing the inhibitory neurotransmitter GABA. 14 A classical genetic association study was presented by Pasquale Strazullo (Department of Clinical and Experimental Medicine, Federico II University of Naples). He presented results from the Olivetti Heart Study, a population based investigation on the genetic, nutritional, and metabolic precursors of cardiovascular disease in 1050 men. In this population, abdominal obesity was associated with a higher rate of proximal tubular sodium reabsorption. Obesity was also associated with a number of genetic polymorphisms that have previously been implicated in the development of hypertension, including the angiotensinogen and angiotensin converting enzyme genes. [17] [18] [19] To close the 'Genetics' Sessions, Friedrich C Luft (Franz-Volhard Klinik and Max Delbruck Center, Medical Faculty of the Charite, Berlin, Germany) discussed the difficulties encountered in the dissection of complex genetic traits. He presented an analysis based on 250 families including a total of 1054 individuals in which variance component analysis, relying on a standard genetic variance model, showed that the genetic variance on LDL explained 27%, on HDL explained 38%, and on the LDL/HDL ratio explained 28% of the total variance, respectively. Genotyping of 88 SNPs in 13 lipid-relevant genes produced 193 haplotypes, which explained most of the genetic variance in LDL, HDL, and LDL/HDL ratio. 20, 21 He also discussed how this family-based approach can be applied to the dissection of other complex traits including blood pressure and BMI. [24] [25] [26] Barbara E Corkey (Obesity Research Centre, Boston University School of Medicine, USA) discussed the importance of the adipocyte in lipid metabolism. She discussed the role of various intracellular proteins in the fatty acid partitioning within the adipocyte. These studies have also resulted in the recognition that acetyl CoA carboxylase but not CPT1 expression regulates fatty acid oxidation. Furthermore, fatty acids or long-chain acetylCoA appear to modulate mitrochondrial energy efficiency. Localization of ACS activity was found to vary under different nutritional conditions and to potentially regulate the fatty acid partitioning by channelling long-chain acetyl CoA to specific sites. 27 Keith Frayn (Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital, Oxford, UK) discussed the importance of adipose tissue as a buffer for fatty acid fluxes in the circulation especially in the period following meals. 28 Adipose tissue provides its buffering action by suppressing the release of nonesterified fatty acids into the circulation and by increasing triacylglycerol clearance. In particular, the pathway of 'fatty acid trapping' (adipocyte uptake of fatty acids liberated from plasma triacylglycerol by lipoprotein lipase) may play a key role in the buffering process. Impairment of this buffering action in obesity exposes extra-adipose tissues to excessive fluxes of lipid fuels, which may accumulate these in the form of triacylglycerol ('ectopic fat deposition'), leading to insulin resistance. 29 Jeremy W Tomlinson (Division of Medical Sciences, University of Birmingham, Queen Elizabeth Hospital, Birmingham, UK) explained how cortisol availability to activate the glucocorticoid receptor is controlled by the enzyme 11b-hydroxysteroid dehydrogenase type 1 (11b-HSD1). In vivo, reductase activity (cortisone to cortisol) predominates and increased activity of 11b-HSD1 in adipose tissue has been postulated as a causative mechanism in the pathogenesis of visceral obesity. 30 However, clinical studies indicate systemic inhibition of 11b-HSD1 reductase activity in obesity. The global inhibition of 11b-HSD1 reductase activity in obesity, and the changes that occur with weight loss, may represent a compensatory mechanism to decrease tissue specific cortisol concentrations and improve insulin sensitivity. Therapeutic inhibition in rodents improves insulin sensitivity and this remains a novel and attractive therapeutic target in patients with type 2 diabetes mellitus and the metabolic syndrome. The importance of adipocyte-derived molecules for the modulation of the metabolic syndrome was also highlighted by Toru Funahashi (Department of Internal Medicine and Molecular Science, Osaka University Graduate School of Medicine, Osaka, Japan), who summarized findings on the adipocyte-specific protein adiponectin, which has been implicated in the development of vascular and metabolic abnormalities. Thus, overexpression of adiponectin suppressed the development of fatty lesions in APO E knockout mice. These mice also showed severe diet-induced insulin resistance compared to wild-type mice. Together these data support the hypothesis that reduced plasma adiponectin levels found in visceral obesity may play a key role in the development of vascular and metabolic complications of obesity. 41, 42 Felipe F Casanueva (Department of Medicine, Endocrine Section, Santiago de Compostela University, Spain) discussed the significance of growth hormone (GH) deficiency in the pathogenesis of obesity. GH is the only pituitary hormone that appears to be under strict metabolic control exerted by nutrients, metabolites, and the status of the energy homeostasis. Thus, changes in body weight are immediately reflected in the pattern of both spontaneous and stimulated GH secretion, and states of malnutrition and negative energy balance are associated with enhanced GH secretion while positive energy balance is associated with reduced GH secretion. Administration of exogenous GH-releasing hormone (GHRH) at saturating doses, or pharmacological inhibition of GH-secretion by somatostatin, did not reverse the obesity associated GH blockade. In contrast, GHRH plus GHRP-6 can release GH in obese patients unresponsive to other stimuli. 43 Although GH is reduced in obesity, this disease cannot be considered a state of GH deficiency, as IGF-I levels are normal, growth in obese children is not disrupted, and no biological endpoints of GH deficiency are obvious in obese individuals. The local role of angiotensin and endothelin in the development of obesity-related vascular lesions was discussed by Matthias Barton (Department of Medicine, University Hospital, Zurich, Switzerland). 44 Especially the selective and endothelin-dependent activation of ACE activity in the kidneys of high-fat fed mice appears to be an important pathogenic factor. Furthermore, activation of the vasocontrictor thromboxane system upon diet-induced obesity interferred with the endothelin system and represents another mechanism of obesity-associated vascular dysfunction. 45 Central mechanisms and the sympathetic nervous system Denis G Baskin (University of Washington and VA Puget Sound Health Care System, Seattle, WA, USA) presented an overview on the central nervous control of energy homeostasis, which is regulated by circulating adiposity signals. 46 Leptin and insulin stimulate hypothalamic POMC neurons that secrete the anorexigenic peptide a-MSH and at the same time inhibit the expression of the orexigenic peptides NPY/ AGRP. Leptin-sensitive POMC neurons in the arcuate nucleus are hypothesized to project to the paraventricular nucleus (PVN), where a-MSH is released to act on neurons projecting to brainstem regions that regulate meal size. He also discussed how a subset of PVN neurons that express oxytocin has direct connection to the nucleus tractus solitarius (NTS) of the brainstem, which receives vagal input from neural and hormonal satiety signals (eg gastric distension, CCK), resulting in meal termination. Thus, pharmacological blockade of oxytocin receptors reverses the anorexic effect of leptin on food intake and also prevents the leptin-stimulated potentiation of CCK-induced Fos expression in the NTS. 47 Paul I Korner (Baker Heart Research Institute, Melbourne and University of New South Wales, Sydney, Australia) 48 discussed the differences between lean essential and obesityassociated hypertension. In early essential hypertension in lean subjects, sympatho-adrenal activitation resembles the hypothalamic defence response, which accounts for the regional and central haemodynamics and the high central blood volume despite reduction in total blood volume. During later stages in essential hypertension, structural cardiovascular changes develop and lower NO availability is associated with greater production of superoxides and Genetics and Molecular Mechanisms AM Sharma et al constrictor autacoids. When normotensive subjects become obese, cardiac output increases, total peripheral resistance falls, while central and total blood volume are raised. In obese hypertensives eccentric left ventricular hypertrophy develops early which, in conjunction with the dyslipidaemias, compounds the risk of ischaemic heart disease. 49 Krzysztof Narkiewicz (Department of Hypertension and Diabetology, Medical University of Gdansk, Poland) discussed the fact that the widespread incidence of obstructive sleep apnea (OSA) in obese subjects significantly contribtutes to cardiovascular complications by increasing sympathetic activity. 50 Remarkably, the high sympathetic drive is present even during daytime wakefulness when subjects are breathing normally and no evidence of hypoxia or chemoreflex activation is apparent. Effective treatment of OSA may attenuate neural and humoral abnormalities in circulatory control, and conceivably reduce the risk of future cardiovascular events. The importance of the peripheral sympathetic nervous system as an important regulator of energy expenditure and metabolism was discussed by Marleen van Baak (Nutrition and Toxicology Research Institute Maastricht (NUTRIM), Department of Human Biology, Maastricht University, The Netherlands). 51 She also discussed how blunting of the thermogenic and lipolytic response to badrenoceptor stimulation may contribute to variations in daily energy expenditure and regulation of body weight regulation. Jens Jordan (Franz-Volhard Clinical Research Center, Humboldt University, Berlin, Germany) discussed the surprising implications of the recent observation that the widely used serotonin and norepinephrine transporter inhibitor sibutramine may have central clonidine-like sympatholytic activities in addition to its well-known peripheral sympathomimetic effects. Thus, the cardiovascular response to the antiobesity drug sibutramine results from opposing peripheral and central nervous effects. 52 William G Haynes (University of Iowa Carver College of Medicine, Iowa City, USA) discussed the concept of selective leptin resistance that may explain why leptin possibly contributes to obesity-related hypertension despite resistance to its effects on appetite and energy expenditure in obese individuals. Relative preservation of leptin-induced sympathoactivation may also contribute to obesity-related NaCl retention, vascular and myocardial hypertrophy, and cardiac arrhythmias.
53,54
Obesity-associated diseases
Nonalcoholic fatty liver (NAFLD) is a common disorder in the Western World, with histological features similar to alcoholic liver disease but is present in the absence of significant alcohol consumption. NAFLD has a spectrum ranging from steatosis alone, to steatosis with varying degrees of necro-inflammation and fibrosis (NASH). Helena Cortez-Pinto (Department of Medicine 2, Centro de Nutric -ão e Metabolismo, Hospital de Santa Maria, Lisboa, Portugal) discussed the role of insulin resistance as a key factor in the pathophysiological abnormalities of patients with NAFLD. Patients with NAFLD have an increase in the basal concentration of free-fatty acids (FFA), and a reduction in insulinmediated suppression of lipolysis, resulting in increased liver fatty acids. There is now strong evidence that fatty livers are exceptionally susceptible to oxidants and develop steatohepatitis when secondary insults generate sufficient oxidants to cause hepatocyte death and inflammation. Furthermore, it has been recently shown that when the adipose tissue depot is expanded, plasma FFA and tumor necrosis factor a (TNF-a) levels increase. TNF-a activates NF-kB in hepatocytes and adipocytes, reducing the tyrosine phosphorylation of the insulin receptor substrate. However, since the transcription of TNF-a is dependent on NF-kB activation, increases in TNF-a will lead to a self-perpetuating cycle of increasing insulin resistance and lipolysis with the release of FFA. 55 According to Luis M Ruilope (Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain), both arterial hypertension and obesity are independent factors facilitating the increase in urinary excretion of albumin, a finding that correlates with the simultaneous presence of an enhanced cardiovascular and renal risk. 56, 57 The obese, hypertensive microalbuminuric patient has to be treated with an aggressive strategy of lifestyle changes plus strict blood pressure control (o130/80 mmHg), which is best obtained by combining an ACE-inhibitor or an angiotensin-receptor blocker with other drugs. Andreas FH Pfeiffer pointed out that differential findings on the relationship between inflammatory cytokines such as TNFa and Interleukin-6 and insulin resistance can be found. Whereas in cellular models these cytokines induce insulin resistance by inhibiting insulin signalling, in vivo studies with neutralizing TNFa by antibodies or Interleukin-6 infusions did not influence glucose homeostasis. However, TNFa and Interleukin-6 are able to increase plasma FFA, and leptin has been shown to increase the production of oxygen species. In summary, the contribution of cytokines to the development of insulin resistance may be indirect, and more closely related to the consequences of insulin resistance and the metabolic syndrome, such as atherosclerosis and type 2 diabetes mellitus. 58, 59 Intervention: diet, exercise and surgery George A Bray (Louisiana State University Medical Center, Pennington Biomedical Research Center, Baton Rouge, Louisiana) discussed the impact of the DASH diet (high in fruits, vegetables, and low-fat dairy products, low in fat, red meats and sugar-containing beverages) to lower blood pressure in obese hypertensives. The DASH diet had its largest effects at higher levels of sodium intake. In these original DASH studies, body weight was controlled. To evaluate the effectiveness of the DASH diet on blood pressure Genetics and Molecular Mechanisms AM Sharma et al and body weight, the PREMIER study was designed. A lifestyle program, and a lifestyle program plus the DASH diet, were compared to a control regime on blood pressure and body weight. The reduction in blood pressure was similar with the two interventions, but there was a trend for a greater decrease in weight in the subgroup eating the DASH diet. Thus, the DASH diet and lower sodium intakes would be a valuable public health strategy to deal with the epidemic of obesity and hypertension. 60 Anthony Kafatos (University of Crete School of Medicine, Heraklion, Crete, Greece) described the significant changes in Cretan diet and lifestyle in recent decades F notably in terms of fat intake F and how these are currently evidenced in rising obesity rates among both adults and children. 61 The most impressive change in the Cretan diet is the increase in the saturated fatty acid intake, from 8% of total energy intake in the 60s to 15-16% in adolescents at present. In contrast, monounsaturated fat intake, mostly derived from olive oil, has been decreased. Paralleling the changes in the Cretan diet, today, one-third of children and more than half the adults in Crete have high or excessively high body weight. Almost 5% of children in Crete have three or more characteristics of the metabolic syndrome while corresponding percentages are 9% for medical students and 19-44% for middle age adults from different professional groups. Rolf Jorde (Medical Department B, University Hospital of North Norway, Tromsø, Norway) discussed the inverse relationship observed between calcium intake and both blood pressure and obesity and the potential involvement of parathormone and vitamin D levels in these effects. However, variations in calcium intake most likely explain only 3% of the variation in body weight. 62 The role of exercise as a modulator of energy balance and its role in weight loss interventions was discussed by Angelo Tremblay (Division of Kinesiology, Laval University, Québec, Canada). 63 Exercise favours macronutrient utilization and also imposes an activation of heart, lung and skeletal muscle to produce an adequate ATP level. Exercise also results in adaptations of the body's biology resulting in improved metabolic fitness in most individuals. Furthermore, trained persons are characterized by a lower body burden of organochlorine pollutants than lean and obese sedentary individuals, even if their food intake is greater over time. Recent data also suggest that the inclusion of physical activity in a weight-reducing program based on a use of sibutramine prevented the occurrence of the cardiostimulating effects of this drug. Carl David Sjöström (Department of Anaesthesiology and Intensive Care, Department of Body Composition and Metabolism, Sahlgrenska University Hospital, Göteborg, Sweden) described the current status of the ongoing Swedish Obesity Study (SOS), where among the first 724 patients, now followed for 10 y, the surgically treated patients still maintained a 16.7% weight loss, while the conventionally treated patients had gained 1.1% of their initial weight. Although there are distinct beneficial effects of long-term weight loss on cardiovascular risk factors, the changes are not as large as might have been expected from short-term studies and are not seen for all risk factors. The relative risk factor changes in the surgically and conventionally treated groups were: glucose À5.4 and þ 20% respectively, Insulin À36 and þ 5.5%, triglycerides À18 and þ 2.4%, Po0.05 for all. Concerning blood pressure, the 16% weight reduction had no effect in terms of incidence in the long-term, but reduced the prevalence of hypertension among initially hypertensive patients. 64, 65 Ongoing weight changes have a strong impact on current blood pressure levels. Furthermore, most risk factors change in relation to time, independently of weight changes.
Conclusion
With over 250 attendees from 54 countries, the Third International Symposium on Obesity and Hypertension (ISOH '03) combined invited lectures of world-known experts in the respective fields and the presentation of around 90 poster on several aspects of obesity and hypertension. Thus, fruitful discussion were made possible between leading scientists and younger researchers. The size of the meeting allowed close interactions both during the lecture and poster sessions and during the breaks providing an important forum for informal exchanges between researchers from different fields. Stimulated by the continuing success of these symposia, the organizers a planning a Fourth Symposium in this series (ISOH'05) in Berlin. A tentative date for this meeting has been set for October 2005.
